Class Action: Janssen Adds GSK’s NS5a Inhibitor To Its Hepatitis C Portfolio
This article was originally published in The Pink Sheet Daily
With protease inhibitor simeprevir filed for approval in the U.S., Europe and Japan, and a non-nucleoside polymerase inhibitor in Phase II, adding GSK2336805, also in Phase II, gives the J&J unit three different classes of oral antiviral candidates for HCV.
You may also be interested in...
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Italy's Chiesi is looking to take a slice of Poland's consumer healthcare market by acquiring infant supplements specialist Smart Pharma.